Eli Lilly and Company
LLY
$734.57
-$16.88-2.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.02% | 101.39% | 1,790.42% | 68.27% | 66.77% |
| Total Depreciation and Amortization | 15.53% | 25.05% | 13.58% | 13.13% | 10.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 560.47% | -169.25% | 119.13% | 21.49% | 294.53% |
| Change in Net Operating Assets | -92.11% | 29.86% | -101.24% | -66.52% | -1,167.15% |
| Cash from Operations | 42.85% | 893.14% | 69.53% | 132.03% | -32.62% |
| Capital Expenditure | -53.05% | -39.73% | -39.20% | -65.92% | -47.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -863.30% | 47.55% | -25.77% | -109.39% | -842.36% |
| Cash from Investing | -184.67% | 34.33% | -30.00% | -378.92% | -70.96% |
| Total Debt Issued | 0.13% | -100.00% | 5,018.14% | -- | 63.00% |
| Total Debt Repaid | 64.48% | -- | -306.23% | -- | -247.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.15% | -14.75% | -15.18% | -15.19% | -14.94% |
| Other Financing Activities | -76.06% | -43.99% | -595.59% | 48.72% | -38.72% |
| Cash from Financing | 543.21% | -106.36% | -63.06% | 250.52% | -175.50% |
| Foreign Exchange rate Adjustments | 471.55% | -431.40% | 4,181.13% | -747.83% | -243.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.14% | -122.98% | 146.35% | 189.66% | -124.23% |